Project Grant R43CA246987

Award Date 8/10/21
Completion Date 1/31/23
Dollars Obligated $1M
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Belmont, CA, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $838,162 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Averto Medical Inc., a medical device company located in Fremont, California. The grant funding supports a clinical trial to evaluate the safety and efficacy of Averto Medical's novel Coloseal ICD System, a minimally invasive medical device designed to eliminate the need for temporary ostomy surgeries in rectal cancer patients. The proposed technology aims to safely divert fecal flow...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), is supporting the development of an automated rapid colonoscope insertion device to improve productivity and reduce injuries for physicians and staff performing colonoscopies. The $399,789 award to Ergami Endoscopy, Inc. will fund the development of a robotic flexible overtube capable of blind automated insertion and fixation in the colon. This...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The General Hospital Corporation (d/b/a Massachusetts General Hospital) provides $1,471,777 to develop and clinically validate new optical coherence tomography (OCT) systems and probes for improved colorectal cancer screening. The key products and services to be delivered include: Creating an OCT system and two distinct OCT imaging probes optimized for adenoma screening. One...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $662,832 to Actuated Medical, Inc. to develop and demonstrate the feasibility of a novel Photoacoustic Visualizer (PAV) system. The PAV aims to improve the accuracy and success rates of sacral nerve stimulation lead placement procedures for treating urinary and bowel incontinence....
This $400,000 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop an improved tracheostoma device for laryngectomy patients. The device is intended to provide better stability, durability, and reduced movement compared to existing tracheostoma buttons, which often fail due to the unique anatomy and needs of each patient. The project plans to leverage advancements in materials science, including high-elongation silicone...
This $274,547 Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a novel Aneurysm Sealing Device (ASD) for endovascular treatment of Abdominal Aortic Aneurysms (AAA). The project seeks to create a device that can completely seal the aneurysm sac, reducing the risk of post-procedure complications and the need for repeat interventions. Key objectives include validating the device's adaptability...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $556,684 to support the "Development of a Bioengineered Therapeutic Device for the Prevention of Lymphedema." The grant, awarded on July 8, 2024, aims to advance the translation of a novel nanofibrillar collagen conduit implant technology developed by Fibralign Corporation to prevent lymphedema, a chronic condition characterized by fluid...
This National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) Project Grant award of $627,422 to the Regents of the University of Michigan aims to develop an engineered commensal bacterial strain that can neutralize the genotoxin colibactin and prevent colorectal cancer associated with colibactin-producing bacteria. Key objectives include: 1) optimizing the surface display of the anti-toxin enzyme ClbS to enhance colibactin removal, 2) evaluating the protective efficacy of the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding to Nous Biosciences Inc., a small disadvantaged business, to develop and evaluate a microsphere-based formulation of the drug dolcanatide, either alone or in combination with the drug sildenafil, for the prevention of colorectal cancer. The $308,650 award, effective from July 1, 2024 to June 30, 2026, supports the specific aims of 1) developing and optimizing drug-loaded...
The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...

A NOVEL DEVICE ALTERNATIVE TO TEMPORARY DIVERTING OSTOMIES AFTER RECTAL CANCER SURGERY - PROJECT SUMMARY/ABSTRACT COLORECTAL CANCER IS THE THIRD MOST COMMON CANCER WITH ABOUT 30-40% OF CASES INVOLVING THE RECTUM. RECTAL CANCER IS TYPICALLY TREATED WITH NEOADJUVANT THERAPY AND SURGICAL RESECTION. HOWEVER, ANASTOMOTIC LEAKS CAN OCCUR IN UP 10-18% OF PATIENTS AFTER RESECTION WITH AN ASSOCIATED HIGH MORTALITY DUE TO SEVERE ABDOMINAL SEPSIS. CURRENTLY, DIVERTING OSTOMIES ARE TYPICALLY PLACED ABOVE THE ANASTOMOSIS TO MITIGATE THE SEVERE CONSEQUENCES OF AN ANASTOMOTIC LEAK, BUT TEMPORARY OSTOMIES THEMSELVES ARE HIGHLY MORBID, HAVE SIGNIFICANT RISK OF MORTALITY, ARE EXPENSIVE TO THE HEALTHCARE SYSTEM, AND DRASTICALLY IMPACT PATIENT'S QUALITY OF LIFE. BECAUSE THE MAJORITY OF PATIENTS DO NOT DEVELOP SEVERE ANASTOMOTIC LEAKS, MOST PATIENTS WHO RECEIVE TEMPORARY OSTOMIES END UP NOT ACTUALLY REQUIRING THEM. THERE EXISTS A MEDICAL NEED TO PROVIDE PROTECTION TO AN ANASTOMOSIS TO PREVENT THE SEVERE CONSEQUENCES OF LEAKS WITHOUT THE MORBIDITY OF A TEMPORARY OSTOMY. SAVAGE MEDICAL HAS DEVELOPED AN INTRALUMINAL FECAL DIVERSION DEVICE THAT UTILIZES A NOVEL ANCHORING MECHANISM THAT IS SAFE, RELIABLE, EASILY REVERSIBLE, AND ELIMINATES THE NEED FOR TEMPORARY OSTOMY SURGERY FOR MOST RECTAL CANCER PATIENTS. THIS TECHNOLOGY ALLOWS FOR ONLY THOSE SMALL PERCENT OF PATIENTS WHO DEVELOP SEVERE LEAKS TO UNDERGO OSTOMY SURGERY WHILE SPARING THE VAST MAJORITY OF RECTAL CANCER PATIENTS FROM REQUIRING AN OSTOMY. ELIMINATING THE NEED FOR A TEMPORARY OSTOMIES WOULD ON AVERAGE SAVE OVER $25K PER PATIENT IN DIRECT SURGICAL COSTS (OSTOMY SURGERY AND REVERSAL SURGERY) AND ELIMINATE $8.5K PER PATIENT IN ANNUAL OSTOMY MAINTENANCE COSTS. THE QUALITY OF LIFE FOR PATIENTS WHO WOULD AVOID OSTOMIES DUE TO THIS TECHNOLOGY WOULD ALSO BE PROFOUNDLY IMPROVED DURING THEIR CANCER TREATMENT. THIS PROPOSED PROJECT IS TO PERFORM DESIGN VERIFICATION TESTING AND LARGE ANIMAL VALIDATION TESTING IN AN ANASTOMOTIC LEAK MODEL FOR THIS NOVEL MEDICAL DEVICE.

Posted 8/10/21, 12:00 AM